Gilead Joins $106B Biopharma M&A Wave, Completes Acquisition of Ouro Medicines
GILD•Gilead participated in a $106B biopharma M&A wave through early June 2026, where average deal size jumped to $527.3M from $365M in 2025. Gilead and Lakefront finalized the acquisition of Ouro Medicines, adding novel inflammation drug candidates to its midstage pipeline.
1. Biopharma M&A Wave Reaches $106B
Global biopharma deal value reached $106B across 201 transactions through early June 2026, with average deal size climbing from $365M in 2025 to $527.3M so far this year. At the current run rate, the sector could surpass $250B in annual deal value, marking its strongest performance since 2019.
2. Gilead Among Top Acquirers
Gilead Sciences joined peers like Merck and Eli Lilly in pursuing strategic asset purchases to mitigate upcoming patent expiries on blockbuster drugs. The company has focused on bolt-on acquisitions in the $1B to $5B range, targeting assets close to commercialization and innovative early-stage technologies.
3. Completion of Ouro Medicines Acquisition
Gilead and Lakefront finalized the acquisition of Ouro Medicines, integrating novel inflammation drug candidates into Gilead’s midstage pipeline. This deal enhances Gilead’s immunology portfolio and supports its long-term growth strategy in inflammatory diseases.
